Explore tweets tagged as #TechBio
$RXRX TECHBIO HANDOFF Q3 rev miss $5M, but Roche $30M milestone hits—partner cash >$500M. CEO Gibson to Chair, Khan in: pivot to scale. -7% to $4.63—oversold trap. $4.60 base, catalysts coiling.
0
0
3
🚀 Big news from @RecursionPharma! Our 2nd Neuroscience Phenomap — a whole-genome map of the brain’s immune cells 🧠 — has been accepted by @Roche & @genentech, triggering a $30M milestone! A massive step toward decoding biology to radically improve lives. 💥 #TechBio #AI
8
32
168
At the intersection of biology and AI, there’s something game changing going on. Dr. Aneil Mallavarapu and his partner – 23andMe co-founder Linea Avey – are both early pioneers in TechBio. This podcast is a conversation I had with Aneil and a live audience of smart friends!
2
1
17
As MassBio wraps up its first incredible journey with the Fall 2025 Drive Techbio cohort, we extend our deepest gratitude to the mentors who dedicated their time and expertise over the past 8 weeks. Learn more: https://t.co/zSGUOJhDWk
#DriveLifeSciences
0
1
2
What it takes to lead in the new era of AI-driven drug discovery. In an interview with Occam, Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD outlines the strategy for building a #TechBio company that’s positioned to win. 🔹 Key factors include: ▪️
4
7
22
💥 The @BIA_UK's just-released annual report noted that TechBio has moved “from a niche field to the mainstream,” and accounts for over 40% of all UK biotech deals in recent years, including Recursion’s £490 million combination with Exscientia in 2024. During the opening keynote
2
12
36
Contrary to some misconceptions, Recursion or $RXRX isn’t just an AI company using synthetic data to enhance drug development. It’s a TechBio platform that combines real lab experiments with machine learning to accelerate drug discovery. Here’s how the flywheel works: 1)
1
6
33
“This isn’t just a tech upgrade. It’s a re-architecture of science itself,” Chris Gibson, CEO of $RXRX, speaking today at GITEX Global 2025 in Dubai. In a packed keynote, Gibson made the case that TechBio—the fusion of AI, biology, and automation—will fundamentally reshape how
Contrary to some misconceptions, Recursion or $RXRX isn’t just an AI company using synthetic data to enhance drug development. It’s a TechBio platform that combines real lab experiments with machine learning to accelerate drug discovery. Here’s how the flywheel works: 1)
0
2
19
We love learning from one another at Recursion. Nowhere was this more evident than our recent TechBio Symposium, where Recursionauts from around the world gathered in Salt Lake City for a two-day, jam-packed series of talks on every aspect of our technology and approach. In this
0
6
28
I’m on-site at @GITEX_GLOBAL in Dubai — witnessing an incredible cross-section of global innovation in applied AI. At 12:55 on the Main Stage (Hall 25), I’ll be sharing how TechBio is fusing AI, Data & DNA to disrupt drug discovery. If you’re here, come say hi! 🌍💊
0
1
22
I’m thrilled to share the latest episode of TechBio Talks featuring my friend and @RecursionPharma scientific advisor, @DrAnneCarpenter of the @broadinstitute of @MIT and @Harvard! 🚀 Anne is a pioneer in image-based profiling, and we had a fantastic conversation that dove deep
2
4
33
🕵Why AI is better suited than humans for early cancer detection. In this clip from the first episode of our TechBio Talks podcast, @BarzilayRegina, AI faculty lead at @AIHealthMIT, tells host Najat Khan about one of the ways AI is having a meaningful impact on patients today
2
3
21
➡️ Where is TechBio headed? Chief R&D Officer and Chief Commercial Officer Najat Khan will present at @HLTHEVENT in Las Vegas on Oct. 21 to share her insights on the rapid acceleration of TechBio alongside @mike_nally, CEO of @generate_biomed for a discussion titled “Oh, the
0
4
21
This tree growing on a power line is the sign you've been waiting for to start building in the techbio space
1
6
64
Inside the AI transformation of drug discovery. On Oct. 15 on the Main Stage of @GITEX_GLOBAL at the Dubai World Trade Center, cofounder and CEO @RecursionChris will give a keynote on "AI, Data & DNA: TechBio’s Disruption of Drug Discovery" – sharing the inside story of how
4
5
34
Ever wonder what the next 5 years of AI in biology & venture will look like? @NathanBenaich (@airstreet) and I unpack it on #TechBioTalks — from AI-first investing to the true moats in TechBio. Catch the full convo → (link in comments)
2
1
12
📣 The inaugural episode of TechBio Talks is now live! Host Najat Khan sits down with @MIT Distinguished Professor & AI faculty lead at @AIHealthMIT @BarzilayRegina for a fascinating conversation about the new AI technologies that are transforming healthcare. 💥 Subscribe and
8
5
18